Tirzepatide

A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes and obesity that achieves greater weight loss than GLP-1 agonists alone.

Also known as: Mounjaro, Zepbound, LY3298176

Regulatory Status

FDA-Approved

Classification date: 2022-05-13

Compounding: Not currently available for compounding

Evidence Summary

Strong50 human studies published

Key Studies

How It Works

Tirzepatide is a novel dual incretin agonist that activates both GIP and GLP-1 receptors, the two primary gut hormones responsible for post-meal insulin secretion. The GIP component enhances fat metabolism and may improve the tolerability of GLP-1-mediated appetite suppression. In head-to-head trials, tirzepatide produced up to 22.5% mean body weight reduction, exceeding semaglutide, and delivered superior HbA1c lowering in patients with type 2 diabetes.

Common Applications

Type 2 diabetes glycemic controlChronic weight managementMetabolic syndrome improvementInsulin resistance reduction

Safety & Considerations

Side effect profile similar to GLP-1 agonists: nausea, diarrhea, vomiting, and constipation are most common and generally transient with dose escalation. Same boxed warning as semaglutide for thyroid C-cell tumors in rodents. Contraindicated in patients with MEN2 or personal/family history of medullary thyroid carcinoma. Monitor for pancreatitis, gallbladder events, and hypoglycemia when combined with insulin or sulfonylureas.

Available Through Our Network

This peptide is available through our partner pharmacies with a valid prescription.

Coming Soon →

Regulatory classifications can change rapidly. The information shown here was last verified on 2022-05-13. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.